Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 20/20 | 1.00 |
| ▸ | LCK | P06239 | 10/20 | 1.00 |
| ▸ | SRC | P12931 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18642945 | 0.92 | RET (1.00) | RETLCKSRC | |
| SCHEMBL19732627 | 0.90 | RET (1.00) | RETLCKSRC | |
| SCHEMBL19732754 | 0.90 | RET (1.00) | RETLCKSRC | |
| SCHEMBL19732655 | 0.90 | RET (1.00) | RETLCKSRC | |
| SCHEMBL19732799 | 0.88 | RET (1.00) | RETLCKSRC | |
| SCHEMBL19732656 | 0.86 | RET (1.00) | RETLCKSRC | |
| SCHEMBL19751384 | 0.85 | RET (0.80) | RETLCKSRC | |
| SCHEMBL19732712 | 0.85 | RET (1.00) | RETLCKSRC | |
| SCHEMBL19732638 | 0.84 | RET (1.00) | RETLCKSRC | |
| SCHEMBL22372651 | 0.82 | RET (0.80) | RETLCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032696-B | Fusion proteins of DCTN1 protein and RET protein | 大鹏药品工业株式会社 | 2023-11-03 | — | — | CN | claimed |
| EP-3260454-B1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2021-06-09 | — | — | EP | claimed |
| CN-108026101-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2020-06-26 | — | — | CN | claimed |
| US-10233189-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-19 | — | — | US | claimed |
| US-10179788-B2 | — | — | 2019-01-15 | — | — | US | claimed |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | claimed |
| EP-3260454-A1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-12-27 | — | — | EP | claimed |
| US-12258376-B2 | Fusion protein of DCTN1 protein with RET protein | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-25 | — | — | US | disclosed |
| CN-111032696-B | Fusion proteins of DCTN1 protein and RET protein | 大鹏药品工业株式会社 | 2023-11-03 | — | — | CN | disclosed |
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-01 | — | — | US | disclosed |
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-01 | — | — | US | disclosed |
| EP-3260454-B1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-10233189-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-10179788-B2 | — | — | 2019-01-15 | — | — | US | disclosed |
| US-10179788-B2 | — | — | 2019-01-15 | — | — | US | disclosed |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| EP-3260454-A1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-12-27 | — | — | EP | disclosed |
| EP-3260454-A1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885LCK 580/4885SRC 153/4885 |
| US-12258376-B2 | Fusion protein of DCTN1 protein with RET protein | DCTN1, RET, DCTN3 | RET 2/4885LCK 2925/4885SRC 2185/4885 |
| US-10179788-B2 | — | RET, GFRA1, GFRA2 | RET 1/4885LCK 879/4885SRC 146/4885 |
| US-10233189-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885LCK 580/4885SRC 153/4885 |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | RET 1/4885LCK 580/4885SRC 153/4885 |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885LCK 580/4885SRC 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.